IL201426A - Drug combination and its use in the treatment of muscle loss - Google Patents

Drug combination and its use in the treatment of muscle loss

Info

Publication number
IL201426A
IL201426A IL201426A IL20142609A IL201426A IL 201426 A IL201426 A IL 201426A IL 201426 A IL201426 A IL 201426A IL 20142609 A IL20142609 A IL 20142609A IL 201426 A IL201426 A IL 201426A
Authority
IL
Israel
Prior art keywords
treatment
drug combination
muscle loss
muscle
loss
Prior art date
Application number
IL201426A
Other languages
English (en)
Hebrew (he)
Other versions
IL201426A0 (en
Original Assignee
Acacia Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0707930A external-priority patent/GB0707930D0/en
Priority claimed from GB0707931A external-priority patent/GB0707931D0/en
Priority claimed from GB0710101A external-priority patent/GB0710101D0/en
Application filed by Acacia Pharma Ltd filed Critical Acacia Pharma Ltd
Publication of IL201426A0 publication Critical patent/IL201426A0/en
Publication of IL201426A publication Critical patent/IL201426A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Nutrition Science (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • AIDS & HIV (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
IL201426A 2007-04-24 2009-10-11 Drug combination and its use in the treatment of muscle loss IL201426A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0707930A GB0707930D0 (en) 2007-04-24 2007-04-24 New therapeutic use
GB0707931A GB0707931D0 (en) 2007-04-24 2007-04-24 New Therapeutic use
GB0710101A GB0710101D0 (en) 2007-05-25 2007-05-25 New Therapeutic use
PCT/GB2008/001452 WO2008129308A2 (en) 2007-04-24 2008-04-24 Drug combination and its use in the treatment of muscle loss

Publications (2)

Publication Number Publication Date
IL201426A0 IL201426A0 (en) 2010-05-31
IL201426A true IL201426A (en) 2016-09-29

Family

ID=39639100

Family Applications (1)

Application Number Title Priority Date Filing Date
IL201426A IL201426A (en) 2007-04-24 2009-10-11 Drug combination and its use in the treatment of muscle loss

Country Status (16)

Country Link
US (1) US8653052B2 (cg-RX-API-DMAC7.html)
EP (1) EP2155180B1 (cg-RX-API-DMAC7.html)
JP (1) JP5627452B2 (cg-RX-API-DMAC7.html)
KR (1) KR101546977B1 (cg-RX-API-DMAC7.html)
CN (2) CN104306381A (cg-RX-API-DMAC7.html)
AU (1) AU2008240379B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0810461A2 (cg-RX-API-DMAC7.html)
CA (1) CA2721739C (cg-RX-API-DMAC7.html)
DK (1) DK2155180T3 (cg-RX-API-DMAC7.html)
EA (1) EA018918B1 (cg-RX-API-DMAC7.html)
ES (1) ES2592289T3 (cg-RX-API-DMAC7.html)
HK (1) HK1202262A1 (cg-RX-API-DMAC7.html)
IL (1) IL201426A (cg-RX-API-DMAC7.html)
MX (1) MX2009011294A (cg-RX-API-DMAC7.html)
NZ (1) NZ580975A (cg-RX-API-DMAC7.html)
WO (1) WO2008129308A2 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1121111B1 (en) 1998-10-15 2010-02-10 Imperial Innovations Limited Compounds for the treatment of weight loss
ATE552032T1 (de) 2005-07-14 2012-04-15 Lithera Inc Verbesserte lipolytikum-formulierung mit hinhaltender wirkstofffreigabe für die arealbehandlung von fettgewebe
GB0624282D0 (en) 2006-12-05 2007-01-10 Cavalla David Treatment of cachexia
JP2013543897A (ja) 2010-11-24 2013-12-09 リセラ，インク． 脂肪症及び輪郭の膨れの美容処置のための、選択的な、親油性の、及び長時間作用性のベータアゴニストの単剤療法製剤、及び方法
TWI724995B (zh) * 2014-08-05 2021-04-21 日商拉夸里亞創藥股份有限公司 作為生長激素釋放肽受體激動劑之絲胺酸衍生物
WO2021145952A1 (en) * 2020-01-13 2021-07-22 Astromedical Biotechnology, Ltd. Use of ketamine in the treatment of cachexia

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0308157B1 (en) 1987-09-15 1997-02-26 The Rowett Research Institute Therapeutic applications of beta-adrenergic agonists
US7101576B2 (en) * 2002-04-12 2006-09-05 Elan Pharma International Limited Nanoparticulate megestrol formulations
DK1494649T3 (da) * 2002-04-12 2012-04-10 Alkermes Pharma Ireland Ltd Nanopartikel-megestrolformuleringer
ES2245612B1 (es) 2004-06-29 2007-08-16 Universidad De Barcelona Nuevo uso terapeutico del formoterol.
EP1991270A4 (en) * 2005-12-22 2009-12-02 Anaborex Inc COMPOSITIONS AND METHODS FOR THE PREVENTION AND TREATMENT OF CACHEXIA
US7947579B2 (en) * 2006-02-13 2011-05-24 Stc.Unm Method of making dense, conformal, ultra-thin cap layers for nanoporous low-k ILD by plasma assisted atomic layer deposition

Also Published As

Publication number Publication date
JP2010525044A (ja) 2010-07-22
EP2155180A2 (en) 2010-02-24
CN104306381A (zh) 2015-01-28
CA2721739C (en) 2016-08-23
US8653052B2 (en) 2014-02-18
EA200970957A1 (ru) 2010-04-30
KR101546977B1 (ko) 2015-08-24
BRPI0810461A2 (pt) 2014-10-14
CN101730547A (zh) 2010-06-09
ES2592289T3 (es) 2016-11-29
EA018918B1 (ru) 2013-11-29
MX2009011294A (es) 2010-01-29
WO2008129308A3 (en) 2009-12-17
IL201426A0 (en) 2010-05-31
NZ580975A (en) 2012-10-26
DK2155180T3 (en) 2016-09-12
EP2155180B1 (en) 2016-07-13
US20100130456A1 (en) 2010-05-27
HK1202262A1 (en) 2015-09-25
AU2008240379B2 (en) 2012-10-04
WO2008129308A2 (en) 2008-10-30
CA2721739A1 (en) 2008-10-30
AU2008240379A1 (en) 2008-10-30
KR20100017205A (ko) 2010-02-16
JP5627452B2 (ja) 2014-11-19

Similar Documents

Publication Publication Date Title
SI1978947T1 (sl) Nitrooksiderivati za uporabo pri zdravljenju mišičnih distrofij
IL216723A0 (en) 1,2,4-thiazolidin-3-one derivatives and their use in the treatment of cancer
GB0719803D0 (en) Therapeutic compounds and their use
GB0719644D0 (en) Therapeutic compounds and their use
GB0724251D0 (en) Therapeutic compounds and their use
GB0722680D0 (en) Therapeutic compounds and their use
PL1912650T3 (pl) Zastosowanie flibanseryny w leczeniu otyłości
IL218851A0 (en) Use of dimiracetam in the treatment of chronic pain
PL2012805T3 (pl) Kompozycja lecznicza i jej zastosowanie
GB0921803D0 (en) Drug composition and its use in therapy
IL201426A0 (en) Drug combination and its use in the treatment of muscle loss
GB2460181B (en) Depsipeptides and their therapeutic use
GB2460178B (en) Depsipeptides and their therapeutic use
GB0919889D0 (en) Drug composition and its use in therapy
GB0919893D0 (en) Drug composition and its use in therapy
GB0910375D0 (en) Drug composition and its use in therapy
GB0710277D0 (en) Use of antivirals in the treatment of medical disorders
GB2460180B (en) Depsipeptides and their therapeutic use
GB0705517D0 (en) Therapeutic compounds and their use
GB0722338D0 (en) Novel use and treatment
PL381819A1 (pl) Sposób oczyszczania i wykorzystania gliceryny odpadowej
GB0712390D0 (en) Use of compounds in the treatment of pain and irritable bowel syndrome
GB0705424D0 (en) Use of compounds in the treatment of pain and irritable bowel syndrome
GB0920267D0 (en) Drug combination and its use in therapy
GB0819103D0 (en) Raphaine compounds and their use in therapy

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees